Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Akero Therapeutics Inc AKRO

Healthcare Biotechnology
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:AKRO)

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm

Newsfile 1 hour ago

Class Action Reminder for NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Reminds Akero Therapeutics, Inc. Investors of Securities Fraud Class Action Lawsuit

Accesswire 18 hours ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO

Newsfile 21 hours ago

Akero Therapeutics (AKRO) SYMMETRY Study Under Fire in Class Action - AKRO Investors with Substantial Losses Encouraged to Contact Hagens Berman by June 25, 2024

Accesswire 23 hours ago

Akero Therapeutics (AKRO) SYMMETRY Study Under Fire in Class Action - AKRO Investors with Substantial Losses Encouraged to Contact Hagens Berman by June 25, 2024

Accesswire 1 day ago

AKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc.

Newsfile 1 day ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO

PR Newswire 1 day ago

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO

Accesswire 2 days ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Newsfile 2 days ago
View More News ››

Opinion & Analysis (NDAQ:AKRO)

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Streetwise Reports July 2, 2020
View More Opinion ››

Bullboard Posts (NDAQ:AKRO)

Akero Therapeutics Reports Positive Phase 2b HARMONY Study D

NEWS: $AKRO Akero Therapeutics Reports Positive Phase 2b HARMONY Study Data2024-03-04 07:22:02 ET DENVER, Colo., Mar 04, 2024...
whytestocks - March 4, 2024

Please take a look

https://www.change.org/p/fda-and-ema-improving-the-public-health?recruiter=1170861947&recruited_by_id=6f0edee0-47cf-11eb-a646...
scarlet1967 - May 26, 2021
View more Bullboard ››

NurExone Biologic Inc.

NurExone Biologic Inc.

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ...
View More »